Merck & Co.
AWARDS
NEWS
Merck and Tokyo-based Eisai Co. have signed a strategic collaboration deal to develop and commercialize Lenvima with Merck’s anti-PD-1 drug Keytruda.
The U.S. Food and Drug Administration (FDA) issued new draft guidance for preclinical trials in Alzheimer’s.
Eli Lilly and Company published results from a new Phase IIIb clinical trial of Trulicity (dulaglutide) in combination with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, which has shown improved blood sugar control in adults with type 2 diabetes.
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
Merck is driving forward in its quest to develop a premier immuno-oncology pipeline by acquiring Australia-based Viralytics Limited and its oncolytic immunotherapy treatments.
Federal court judge orders Merck to repay $2.5 Billion to Gilead in overturned patent decision.
JOBS
IN THE PRESS